Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines

Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines

In view of the inequitable distribution of COVID-19 vaccines, several initiatives have been discussed to waive respective patent rights. This article provides a fact-based multinational study on patent rights protecting BioNTech-Pfizer's vaccine BNT162b2. We conclude that although there actuall...

Full description

Saved in:
Bibliographic Details
Published in:Biotechnology law report Vol. 41; no. 2; pp. 86 - 92
Main Authors: Duarte, Raildo, Khan, Hasan Irfan, Luna, Alejandro, Amin, Ramadan, Yadav, Charul, Storz, Ulrich
Format: Journal Article
Language:English
Published: New Rochelle Mary Ann Liebert, Inc 01-04-2022
Subjects:
Coronaviruses
COVID-19 vaccines
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In view of the inequitable distribution of COVID-19 vaccines, several initiatives have been discussed to waive respective patent rights. This article provides a fact-based multinational study on patent rights protecting BioNTech-Pfizer's vaccine BNT162b2. We conclude that although there actually is a vaccine shortage in many countries, patents cannot be blamed as the scapegoat for said situation.
ISSN:0730-031X
1557-8704
DOI:10.1089/blr.2022.29265.us